These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27259590)

  • 21. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
    Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Jabbour E; Kantarjian H; O'Brien S; Shan J; Quintas-Cardama A; Faderl S; Garcia-Manero G; Ravandi F; Rios MB; Cortes J
    Blood; 2011 Oct; 118(17):4541-6; quiz 4759. PubMed ID: 21803854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
    Cortes JE; Kantarjian HM; Goldberg SL; Powell BL; Giles FJ; Wetzler M; Akard L; Burke JM; Kerr R; Saleh M; Salvado A; McDougall K; Albitar M; Radich J;
    J Clin Oncol; 2009 Oct; 27(28):4754-9. PubMed ID: 19720924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
    Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
    Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
    [No Abstract]   [Full Text] [Related]  

  • 26. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
    Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
    Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
    Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
    Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High
    Vigneri P; Stagno F; Stella S; Cupri A; Forte S; Massimino M; Antolino A; Siragusa S; Mannina D; Impera SS; Musolino C; Malato A; Mineo G; Tomaselli C; Murgano P; Musso M; Morabito F; Molica S; Martino B; Manzella L; Müller MC; Hochhaus A; Raimondo FD
    Clin Cancer Res; 2017 Dec; 23(23):7189-7198. PubMed ID: 28928163
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
    Takahashi N; Miura I; Kobayashi Y; Kume M; Yoshioka T; Otane W; Ohtsubo K; Takahashi K; Kitabayashi A; Kawabata Y; Hirokawa M; Nishijima H; Ichinohasama R; Decoteau J; Miura AB; Sawada K
    Int J Hematol; 2005 Apr; 81(3):235-41. PubMed ID: 15814334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
    DeAngelo DJ; Chen L; Guerin A; Styles A; Giguere-Duval P; Wu EQ
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):245-51. PubMed ID: 24393622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
    Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
    Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
    Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Ravandi F; Jabbour E; Shan J; Cortes J
    Cancer; 2012 Jun; 118(12):3116-22. PubMed ID: 22370904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
    García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
    PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
    Lai Y; Qin Y; Huang X; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
    Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
    Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
    Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
    [No Abstract]   [Full Text] [Related]  

  • 40. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
    Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
    J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.